30 closest matches · ranked by relevance
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
Renal Insufficiency, Chronic
Primary: Number of Participants With a Urine Albumin Excretion Decrease of 20% or More — 19; 13 Participants — p=0.257
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
Kidney Failure, Chronic
Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Diabetes Mellitus, Type 2 · Chronic Renal Insufficiency
Primary: Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment — 41; 16; 8; 1 Participants
Chronic Renal Failure
Primary: Change in Daily Urine Volume From Baseline — 18.3 mL
Anemia
Primary: Patients With an Increase in Hemoglobin >= 1gm/dL. — 35; 23 participants
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
Acute Renal Failure
Primary: 60 Day Mortality — 11 Participants
Secondary Hyperparathyroidism · Chronic Renal Insufficiency
Primary: Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase — 15; 5 Participants — p=0.006
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Renal Insufficiency, Chronic · Hypertension
Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg
Chronic Renal Failure
Primary: Change From Baseline in Daily Urine Volume — 481.0 ml
Chronic Renal Insufficiency · Proteinuria
Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
End-stage Renal Disease (ESRD)
Primary: Peak Oxygen Consumption — 3.07 ml/min/kg
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Chronic Kidney Disease
Primary: Systolic Blood Pressure (SBP) — 135.1; 134.4 mmHg — p=0.57
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008
Hemodialysis-Induced Symptom · Mitochondrial Diseases
Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
Anemia
Primary: Median Time to First Cardiovascular Event — NA; NA days — p=0.2036
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L
Chronic Kidney Disease
Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale
Chronic Kidney Disease
Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05
Hyperphosphatemia
Primary: Change From Baseline in Serum Phosphorus at Week 8 — 2.090; 2.095; 0.010; -0.200 mmol/L — p=<0.0001